Table 1 Demographic characteristics of 43 patients who received daptomycin-based antimicrobial therapy
Characteristic | (n, %) |
|---|---|
Gender | |
Female | 18 (42) |
Male | 25 (58) |
Mean age, years (range) | 61 (18–88) |
Age groups | |
< 65 years | 25 (58) |
≥ 65–< 75 years | 8 (19) |
≥ 75 years | 10 (23) |
Mean body weight, kg (range) | 75 (32–110) |
Mean body mass index (range) | 27 (14–43) |
BMI ≥ 25, < 30 | 9 (21) |
BMI ≥ 30 | 14 (33) |
Ethnicity (caucasian) | 42 (98) |
Active smoking | 10 (23) |
Underlying diseases | |
Hypertension | 17 (40) |
Diabetes mellitus | 5 (12) |
Cardiovascular disease | 13 (30) |
Cancer | 6 (14) |
Creatinine clearance (MDRD) 30–60 mL/min | 3 (7) |
Immunosuppression | 4 (9) |
Mean ASA score (range) | 2.2 (1–4) |
Past episode of BJI on the same site | 27 (63) |
Anatomical site of infection | |
Knee | 12 (28) |
Hip | 9 (21) |
Lower limb | 9 (21) |
Rachis | 8 (19) |
Upper limb | 2 (5) |
Other | 1 (2) |
Chronic osteomyelitis | 37 (86) |
Physiopathology of osteomyelitis | |
Post-operative | 41 (95) |
Hematogenous infection | 2 (5) |
Pressure ulcer | 2 (5) |
Orthopedic device | |
Prosthesis | 23 (53) |
Osteosynthesis device | 14 (33) |
None | 6 (14) |
Previous exposition to antimicrobials for the index BJI before daptomycin prescription | |
Glycopeptides | 37 (86) |
Fluoroquinolones | 27 (63) |
Rifampin | 25 (58) |
Clindamycin, pristinamycin | 18 (42) |
Piperacillin tazobactam | 15 (35) |
Cephalosporins | 13 (30) |
Fosfomycin | 13 (30) |
Oxacillin, cloxacillin | 12 (28) |
Aminoglycosids | 9 (21) |
Fucidic acid | 7 (16) |
Linezolid | 5 (12) |
Others | 18 (42) |